Mauna Kea Technologies

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

Retrieved on: 
Monday, November 13, 2023

Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.

Key Points: 
  • Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.
  • Mauna Kea is a leading medical device company pioneering the development of real-time intraoperative visualisation of cancer tissue during surgery.
  • Mauna Kea's Cellvizio confocal laser endomicroscopy (CLE) in vivo cellular imaging platform has received U.S. Food and Drug Administration (FDA) approval and is CE Marked for a range of applications.
  • Following closing (on 17 November 2023), Telix will own 19.33% of the share capital and 19.01% of the voting rights of Mauna Kea.

Telix and Mauna Kea Technologies to Expand Collaboration in Urologic Oncology Surgery

Retrieved on: 
Monday, November 13, 2023

Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.

Key Points: 
  • Telix's investment in Mauna Kea will further support the development of advanced imaging techniques for minimally invasive (laparoscopic and robotic) surgery, with a specific focus on urologic oncology.
  • Mauna Kea is a leading medical device company pioneering the development of real-time intraoperative visualisation of cancer tissue during surgery.
  • Mauna Kea's Cellvizio confocal laser endomicroscopy (CLE) in vivo cellular imaging platform has received U.S. Food and Drug Administration (FDA) approval and is CE Marked for a range of applications.
  • Following closing (on 17 November 2023), Telix will own 19.33% of the share capital and 19.01% of the voting rights of Mauna Kea.

Caption Health Names Joseph DeVivo to Board of Directors

Retrieved on: 
Wednesday, December 1, 2021

BRISBANE, Calif., Dec. 1, 2021 /PRNewswire/ -- Caption Health , the leader in using AI to improve heart ultrasound diagnostics, today announced the addition of Joseph DeVivo, President, Hospitals and Health Systems at Teladoc Health, to its board of directors.

Key Points: 
  • BRISBANE, Calif., Dec. 1, 2021 /PRNewswire/ -- Caption Health , the leader in using AI to improve heart ultrasound diagnostics, today announced the addition of Joseph DeVivo, President, Hospitals and Health Systems at Teladoc Health, to its board of directors.
  • "We are thrilled to welcome Joe to the board at a time when Caption Health is poised to reshape the market," said Steve Cashman, Caption Health President and CEO.
  • "Caption Health is making rapid progress in helping enable access to high-quality and affordable cardiac ultrasounds in any care setting.
  • "Caption Health's success in getting cardiac ultrasound into the hands of non-experts is truly impressive," said Mr. DeVivo.

Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021

Retrieved on: 
Monday, October 4, 2021

This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.

Key Points: 
  • This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.
  • Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.
  • 2 The legal entity of the Lung Cancer Initiative at Johnson & Johnson is Johnson & Johnson Enterprise Innovation, Inc.

Telix Pharmaceuticals Limited and Mauna Kea Technologies Announce the “Imaging and Robotics in Surgery (IRiS) Alliance”

Retrieved on: 
Tuesday, December 15, 2020

The Telix and Mauna Kea scientific and clinical research collaboration is called the Imaging and Robotics in Surgery (IRiS) Alliance, or IRiS Alliance, and was created to further develop the combined technological capabilities of both companies.

Key Points: 
  • The Telix and Mauna Kea scientific and clinical research collaboration is called the Imaging and Robotics in Surgery (IRiS) Alliance, or IRiS Alliance, and was created to further develop the combined technological capabilities of both companies.
  • We are excited to announce this exclusive scientific and clinical research collaboration with Telix in the field of urologic oncology, said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies.
  • Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.

Mauna Kea Technologies: Cellvizio® Endorsed By the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) as a Safe and Effective Diagnostic Tool

Retrieved on: 
Tuesday, May 26, 2020

TAVACs objective was to evaluate the safety, value, and efficacy of CLE in the gastrointestinal tract.

Key Points: 
  • TAVACs objective was to evaluate the safety, value, and efficacy of CLE in the gastrointestinal tract.
  • Early diagnosis and effective surveillance can have significant positive impacts on therapeutic management, and Cellvizio is an essential tool to improve diagnostic accuracy and reduce inappropriate interventions.
  • SAGES (The Society of American Gastrointestinal and Endoscopic Surgeons) was founded in 1981 to foster, promote, support and encourage academic, clinical and research achievement in gastrointestinal endoscopic surgery.
  • For more information on Mauna Kea Technologies, visit www.maunakeatech.com
    This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.

Mauna Kea Technologies Receives FDA Clearance And CE Marking For Its Next-Generation Cellvizio® Platform

Retrieved on: 
Tuesday, March 3, 2020

This marks the 18th U.S. FDA 510(k) clearance of the Cellvizio pCLE/nCLE platform.

Key Points: 
  • This marks the 18th U.S. FDA 510(k) clearance of the Cellvizio pCLE/nCLE platform.
  • "We are proud to announce the FDA clearance and CE marking of our next generation Cellvizio in the USA and in Europe," said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies.
  • For more information on Mauna Kea Technologies, visit www.maunakeatech.com
    This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.

Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination

Retrieved on: 
Monday, January 27, 2020

Real-world data, published in multiple peer-reviewed medical journals by leading investigators, paved the way for this new FDA clearance.

Key Points: 
  • Real-world data, published in multiple peer-reviewed medical journals by leading investigators, paved the way for this new FDA clearance.
  • This new FDA clearance of our Cellvizio platform in combination with a fluorescent dye is a major regulatory milestone for Mauna Kea Technologies.
  • This clearance is another step for Mauna Kea Technologies in an accelerated development of drug-device combination indications, enabling the clinical use of Cellvizio with highly specific molecular imaging markers.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.

Mauna Kea Technologies Announces Publication of Positive Results on Needle-Based Endomicroscopy for the Clinical Management of Pancreatic Cystic Lesions

Retrieved on: 
Wednesday, January 8, 2020

The article, entitled Impact of EUS-guided microforceps biopsy and needle-based confocal laser endomicroscopy on the diagnostic yield and clinical management of pancreatic cystic lesions was published in Gastrointestinal Endoscopy (2019, DOI: 10.1016/j.gie.2019.12.022 ).

Key Points: 
  • The article, entitled Impact of EUS-guided microforceps biopsy and needle-based confocal laser endomicroscopy on the diagnostic yield and clinical management of pancreatic cystic lesions was published in Gastrointestinal Endoscopy (2019, DOI: 10.1016/j.gie.2019.12.022 ).
  • The management of PCLs using SOC is further challenged by the lack of optimal diagnostics and divergent patient management guidelines.
  • For more information on Mauna Kea Technologies, visit www.maunakeatech.com
    This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.

Mauna Kea Technologies Announces Strategic Equity Investment of €7.5 Million by Johnson & Johnson Innovation

Retrieved on: 
Monday, December 16, 2019

Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced a strategic equity investment of 7.5 million euro by Johnson & Johnson Innovation JJDC, Inc. (JJDC).

Key Points: 
  • Mauna Kea Technologies (Paris:MKEA) (OTCQX:MKEAY) (Euronext: MKEA) inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced a strategic equity investment of 7.5 million euro by Johnson & Johnson Innovation JJDC, Inc. (JJDC).
  • We are very proud to announce a strategic equity investment agreement with Johnson & Johnson Innovation JJDC, Inc., said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies.
  • This agreement represents a significant strategic inflection point for Mauna Kea Technologies, particularly in that it provides a capital infusion that will help us execute our strategic growth initiatives.
  • The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time.